Horizon / Plein textes La base de ressources documentaires de l'IRD

IRD

 

Publications des scientifiques de l'IRD

Gini R., Fournie X., Dolk H., Kurz X., Verpillat P., Simondon François, Strassmann V., Apostolidis K., Goedecke T. (2019). The ENCePP Code of Conduct : a best practise for scientific independence and transparency in noninterventional postauthorisation studies. Pharmacoepidemiology and Drug Safety, 28 (4), 422-433. ISSN 1053-8569

Fichier PDF disponiblehttp://horizon.documentation.ird.fr/exl-doc/pleins_textes/divers19-06/010075717.pdf[ PDF Link ]

Lien direct chez l'éditeur doi:10.1002/pds.4763

Titre
The ENCePP Code of Conduct : a best practise for scientific independence and transparency in noninterventional postauthorisation studies
Année de publication2019
Type de documentArticle référencé dans le Web of Science WOS:000467999700002
AuteursGini R., Fournie X., Dolk H., Kurz X., Verpillat P., Simondon François, Strassmann V., Apostolidis K., Goedecke T.
SourcePharmacoepidemiology and Drug Safety, 2019, 28 (4), p. 422-433. ISSN 1053-8569
RésuméPurpose: The ENCePP Code of Conduct provides a framework for scientifically independent and transparent pharmacoepidemiological research. Despite becoming a landmark reference, practical implementation of key provisions was still limited. The fourth revision defines scientific independence and clarifies uncertainties on the applicability to postauthorisation safety studies requested by regulators. To separate the influence of the funder from the investigator's scientific responsibility, the Code now requires that the lead investigator is not employed by the funding institution. Method: To assess how the revised Code fits the ecosystem of noninterventional pharmacoepidemiology research in Europe, we first mapped key recommendations of the revised Code against ISPE Good Pharmacoepidemiology Practices and the ADVANCE Code of Conduct. We surveyed stakeholders to understand perceptions on its value and practical applicability. Representatives from the different stakeholders' groups described their experience and expectations. Results: Unmet needs in pharmacoepidemiological research are fulfilled by providing unique guidance on roles and responsibilities to support scientific independence. The principles of scientific independence and transparency are well understood and reinforce trust in study results; however, around 70% of survey respondents still found some provisions difficult to apply. Representatives from stakeholders' groups found the new version promising, although limitations still exist. Conclusion: By clarifying definitions and roles, the latest revision of the Code sets a new standard in the relationship between investigators and funders to support scientific independence of pharmacoepidemiological research. Disseminating and training on the provisions of the Code would help stakeholders to better understand its advantages and promote its adoption in noninterventional research.
Plan de classementSanté : généralités [050]
Descr. géo.EUROPE
LocalisationFonds IRD [F B010075717]
Identifiant IRDfdi:010075717
Lien permanenthttp://www.documentation.ird.fr/hor/fdi:010075717

Export des données

Disponibilité des documents

Télechargment fichier PDF téléchargeable

Lien sur le Web lien chez l'éditeur

Accès réservé en accès réservé

HAL en libre accès sur HAL


* PDF Link :

    à télécharger pour citer/partager ce document sur les réseaux sociaux académiques


Accès aux documents originaux :

Le FDI est labellisé CollEx

Accès direct

Bureau du chercheur

Site de la documentation

Espace intranet IST (accès réservé)

Suivi des publications IRD (accès réservé)

Mentions légales

Services Horizon

Poser une question

Consulter l'aide en ligne

Déposer une publication (accès réservé)

S'abonner au flux RSS

Voir les tableaux chronologiques et thématiques

Centres de documentation

Bondy

Montpellier (centre IRD)

Montpellier (MSE)

Cayenne

Nouméa

Papeete

Abidjan

Dakar

Niamey

Ouagadougou

Tunis

La Paz

Quito